sacituzumab govitecan
gilead sciences
['tropics-02', 'sacituzumab govitecan', 'breast']
results from tropics-02 trial presented at #asco22 show a statistically significant but small increase in pfs for sacituzumab govitecan versus treatment of physician s choice for patients with hr+/her2- #breastcancer. small increase due to heavy pretreatment and population? 
Husband, Father, Scientist, Teacher, Traveler, Foodie, Outdoorsy. Tweets are my own and not necessarily an endorsement.